Guessing some grant funding from the US Government. That would...

Guessing some grant funding from the US Government. That would be so good - and the end of the dreaded ATM

Grant funding was mentioned a couple of times from the US company Kintara Therapeutics in this presentation overnight.

Definitely worth a listen - as Kintara's VAL -083 commenced in GBM AGILE, at the same time as Paxalisib (Jan 2021). Simple to register and 10 minutes of enlightening discussion, from their CEO.  You will have to source the link away from the paste below, I have provided.

Some key points though, besides the likely grant funding.

* In a previous breast cancer trial run by this GLOBAL COALITION GROUP - 3 new breast cancer drugs were actually approved.

* TMZ - the control drug study has finished, (many months ago, it seems to be the case). The control arm only dossed 20% of all the patients in GBM AGILE and commenced way back in 2019. Control arm following its conclusion - will now be marked against other investigational drugs in the study.

* No mention whatsoever of a Phase 2..... or VAL -083 moving to Phase 2 .

* Very strong support from the FDA - including personnel interaction with the CEO - and a senior person from the FDA re GBM AGILE

* Full details from the control study will be released - even a beat of a few weeks will or should see VAL -083 approved.

-------------------------------------------------------
So once again extremely positive snippets of information out there - for paxalisib in GBM AGILE.  It is not a head to head new GBM drug race. Seemingly the key is OS - your drug verse the control. (D0zens of breast cancer drugs continue to be approved - but not since 1999, has there been a new GBM drug aka TMZ )

Paxalisib now has an outstanding world pedigree of deep study into how inhibition (repair) of how the PI3K pathway works..... to fight cancer. Also much research is taking place as to how paxalisib - in other drug combination and radiation might work.

Wish the best to the novel Kintara drug.... it may get approved also, but suggest Paxalisib has a much broader and deeper potential.

An outstanding situation here - with rarely or never seen previous potential for SP appreciation. NOTE in particular, recent links to these senior GBM AGILE people - referencing TMZ as being ineffective in unmethylated GBM








Kintara Therapeutics, Inc.
Tue, Jan 10, 2023 11:29 AM PST (Wed, Jan 11, 2023 5:29 AM AEST)
Already registered for an event in this series? Log In Now

Email:
mce-anchor
Complete this form to enter the webcast.
(* indicates required field)
First Name*:Last Name*:Company*:Email*:


FAQs and System Test